Welcome to the e-CCO Library!

P418: Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Czubkowski*, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus

Created: Friday, 22 February 2019, 9:49 AM
P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Bressler1, A. Yarur2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, G.J. Mantzaris12

Created: Thursday, 30 January 2020, 10:12 AM
P419: Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yoshihara T., Shinzaki S., Kawai S., Iwatani S., Yamaguchi T., Araki M., Hiyama S., Inoue T., Hayashi Y., Watabe K., Iijima H., Takehara T.

Created: Wednesday, 20 February 2019, 10:36 AM
P419: Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Höög*, M. Eberhardson, S. Almer

Created: Friday, 22 February 2019, 9:49 AM
P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Pekala*, R. Filip

Created: Thursday, 21 February 2019, 9:14 AM
P419: Long-term outcome of ulcerative colitis in pediatric patients who achieved mucosal and histological healing: a real-life referral center experience
Year: 2022
Source: ECCO'22
Authors: Scarallo, L.(1);Peruggia, E.(2);Fioretti, L.(1);Renzo, S.(1);Paci, M.(1);Naldini, S.(1);Barp, J.(1);Di Paola, M.(1);Lionetti, P.(1,3);
Created: Friday, 11 February 2022, 3:52 PM
P419: Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Eqbal, A.(1)*;Hilley, P.(1);Gilmore, R.(1);Li Wai Suen, C.(1);Choy, M.(1,2);De Cruz, P.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P419: Outcomes for patients with severe acute ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Shivakumar*1, R. Grant2, R. Lynch2, T. Manship3, F. Jagger3, J. Satsangi4, G. T. Ho3, N. Plevris3, C. Lees5, I. Arnott3

Created: Friday, 22 February 2019, 9:41 AM
P419: Psychological acceptability of surgery in patients with ulcerative colitis after total colectomy
Year: 2021
Source: ECCO'21 Virtual
Authors: Itabashi, M.(1);Hirano, Y.(2,3);Saito, T.(4,5);Inoue, M.(6);Uchida, K.(6);Arai, K.(3);Minakuchi, E.(2);Ishihara, H.(2);Onizawa, R.(2);Hirayama, A.(2);Araki, K.(2);Kimura, H.(2);Kunisaki, R.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Wagner1, J. Mansfield2, C. Geier1, A. Dash3, Y. Wang3, C. Li3, A. Lekkerkerker3, T. Lu3

Created: Thursday, 30 January 2020, 10:12 AM
P420: Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrence
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Auzolle C.*1, Houze P.2, Tran-Minh M.-L.1, Nancey S.3, Buisson A.4, Fumery M.5, Pariente B.6, Djenidi F.1, Marteau P.7, Bouhnik Y.8, Seksik P.7, Allez M.7

Created: Wednesday, 20 February 2019, 10:36 AM
P420: Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemia
Year: 2021
Source: ECCO'21 Virtual
Authors: Akriche, F.(1);Jacob, I.(2);Schmidt, C.(3);Howaldt, S.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P420: Correlation between Infliximab trough levels and endoscopic activity in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Bernardo*1, S. Fernandes1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Marinho1

Created: Friday, 22 February 2019, 9:41 AM
P420: Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Klett*, D. Strobel, D. Wildner, R. Atreya, M. F. Neurath, R. S. Görtz

Created: Friday, 22 February 2019, 9:49 AM
P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Gheorghe1, P. Svoboda2, A. Dimitriu1*, B. Mateescu3, I. Kotzev4

Created: Thursday, 21 February 2019, 9:14 AM
P420: Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
Year: 2022
Source: ECCO'22
Authors: Melotti, L.(1);Dussias, N.K.(1);Belluzzi, A.(1);Salice, M.(1);Calabrese, C.(1);Rizzello, F.(1);Gionchetti, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P420: Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Holubar, S.(1)*;Cohen, B.(2);Uchino, T.(1);Lincango, E.(1);Prien, C.(1);Joseph, A.(2);Achkar, J.P.(2);Gunter, R.(1);Lashner, B.(2);DeLaney, C.(3);Ban, K.(1);Bolshinsky, V.(1);Lipman, J.(1);Liska, D.(1);Philpott, J.(2);Naseer, M.(2);Kanters, A.(1);Braga-Neto, M.(2);Rieder, F.(2);Somovilla, J.(1);Qazi, T.(2);Regueiro, M.(2);Hull, T.(1);Steele, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Dubois, A. Moens, J. Sabino, M. Ferrante, S. Vermeire

Created: Thursday, 30 January 2020, 10:12 AM
P421: Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P421: Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn's disease
Year: 2022
Source: ECCO'22
Authors: Albshesh, A.(1);Ungar, B.(1);Kopylov, U.(1);Ben-Horin, S.(1);Carter , D.(1);
Created: Friday, 11 February 2022, 3:52 PM